Alimera Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full-Year 2020
January 19, 2021 at 04:38 pm EST
Share
Alimera Sciences, Inc. provided revenue guidance for the fourth quarter and full-year 2020. For the period, the company expects to report consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million
For the full year, the company expects annual 2020 consolidated net revenue in excess of $50.5 million.
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
ALIMERA SCIENCES, INC. 
